Further, we found that high copy number of MAP4K1 showed consistent association with both recurrence and survival for patients with stage III CRC patients receiving oxaliplatin-based chemotherapy, highlighting the important role of MAP4K1 in modulating oxaliplatin response and its potential as a biomarker for the efficacy of oxaliplatin-based chemotherapy. Here, MAP4K1 is linked to colorectal carcinoma.